{"id":67179,"date":"2026-06-03T13:47:53","date_gmt":"2026-06-03T05:47:53","guid":{"rendered":"https:\/\/flcube.com\/?p=67179"},"modified":"2026-06-03T13:47:53","modified_gmt":"2026-06-03T05:47:53","slug":"cspc-pharmaceutical-receives-nmpa-approval-for-first-in-class-mrna-lnp-dual-target-car-t-therapy-sys-6063-in-systemic-lupus-erythematosus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67179","title":{"rendered":"CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced it has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>SYS 6063<\/strong>, an innovative <strong>mRNA-LNP-based dual-target chimeric antigen receptor (CAR)-T therapy<\/strong> designed to treat <strong>relapsed\/refractory systemic lupus erythematosus (SLE)<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This marks a significant milestone as one of the first applications of <strong>CAR-T cell therapy<\/strong>\u2014traditionally used in oncology\u2014for the treatment of <strong>autoimmune disease<\/strong>, potentially addressing fundamental limitations of current SLE therapies that fail to provide curative outcomes and are associated with high relapse rates.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-development-status\" class=\"wp-block-heading\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Product Name<\/strong><\/td><td>SYS 6063<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>mRNA-LNP (messenger RNA &#8211; Lipid Nanoparticle)<\/td><\/tr><tr><td><strong>Therapy Class<\/strong><\/td><td>Dual-target CAR-T cell therapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed\/refractory systemic lupus erythematosus (SLE)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical completed, clinical trials authorized<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-novel-therapeutic-mechanism\" class=\"wp-block-heading\">Novel Therapeutic Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Targets<\/strong>: Simultaneously targets <strong>CD19<\/strong> (cluster of differentiation 19) and <strong>BCMA<\/strong> (B-cell maturation antigen)<\/li>\n\n\n\n<li><strong>Precision Elimination<\/strong>: CARs specifically recognize and eliminate CD19- and BCMA-positive pathogenic B cells<\/li>\n\n\n\n<li><strong>Root Cause Approach<\/strong>: Addresses disease at cellular source rather than symptomatic management<\/li>\n\n\n\n<li><strong>Delivery System<\/strong>: mRNA-LNP platform enables in vivo CAR expression without ex vivo cell manipulation<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Eliminates autoreactive B-cell populations responsible for autoantibody production and disease progression<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-evidence\" class=\"wp-block-heading\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Cell Killing<\/strong><\/td><td>Significant elimination of CD19- and BCMA-positive cells<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable safety in preclinical models<\/td><\/tr><tr><td><strong>Efficacy<\/strong><\/td><td>Demonstrated therapeutic activity in relevant disease models<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First dual-target approach combining CD19 + BCMA for SLE<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-for-cspc-pharmaceutical\" class=\"wp-block-heading\">Strategic Implications for CSPC Pharmaceutical<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation<\/strong>: Success would validate CSPC&#8217;s mRNA-LNP delivery platform for autoimmune applications<\/li>\n\n\n\n<li><strong>First-Mover Advantage<\/strong>: Positions CSPC as pioneer in CAR-T therapy for autoimmune diseases in China<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Addresses significant unmet need in SLE treatment with estimated 1 million patients in China alone<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Positive results could facilitate international partnerships and regulatory filings<\/li>\n\n\n\n<li><strong>Pipeline Diversification<\/strong>: Expands CSPC&#8217;s portfolio beyond traditional small molecules into advanced cell and gene therapies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current SLE Treatments<\/strong>: Limited to immunosuppressants, corticosteroids, and biologics with modest efficacy and high relapse rates<\/li>\n\n\n\n<li><strong>CAR-T in Autoimmunity<\/strong>: Emerging field with early promising data from other companies in Europe and US<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Dual-target approach may provide more comprehensive B-cell depletion than single-target strategies<\/li>\n\n\n\n<li><strong>Manufacturing Advantage<\/strong>: mRNA-LNP platform potentially offers simpler manufacturing compared to traditional ex vivo CAR-T approaches<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-considerations\" class=\"wp-block-heading\">Market Impact Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treatment Paradigm Shift<\/strong>: Could transform SLE from chronic management to potential functional cure<\/li>\n\n\n\n<li><strong>Pricing Premium<\/strong>: Advanced therapy pricing likely justified by curative potential and reduced long-term healthcare costs<\/li>\n\n\n\n<li><strong>Patient Access<\/strong>: Initial focus on severe relapsed\/refractory cases before potential expansion to earlier disease stages<\/li>\n\n\n\n<li><strong>Healthcare Infrastructure<\/strong>: Requires specialized centers capable of managing advanced therapy administration<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for SYS 6063. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060202052_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060202052_c.\"><\/object><a id=\"wp-block-file--media-37978d62-b136-4816-b8e1-3adf06392f94\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060202052_c.pdf\">2026060202052_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060202052_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-37978d62-b136-4816-b8e1-3adf06392f94\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[171,855],"class_list":["post-67179","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for SYS 6063, an innovative mRNA-LNP-based dual-target chimeric antigen receptor (CAR)-T therapy designed to treat relapsed\/refractory systemic lupus erythematosus (SLE).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67179\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for SYS 6063, an innovative mRNA-LNP-based dual-target chimeric antigen receptor (CAR)-T therapy designed to treat relapsed\/refractory systemic lupus erythematosus (SLE).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67179\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-03T05:47:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67179#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67179\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus\",\"datePublished\":\"2026-06-03T05:47:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67179\"},\"wordCount\":494,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67179#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67179\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67179\",\"name\":\"CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-03T05:47:53+00:00\",\"description\":\"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for SYS 6063, an innovative mRNA-LNP-based dual-target chimeric antigen receptor (CAR)-T therapy designed to treat relapsed\\\/refractory systemic lupus erythematosus (SLE).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67179#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67179\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67179#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for SYS 6063, an innovative mRNA-LNP-based dual-target chimeric antigen receptor (CAR)-T therapy designed to treat relapsed\/refractory systemic lupus erythematosus (SLE).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67179","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus","og_description":"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for SYS 6063, an innovative mRNA-LNP-based dual-target chimeric antigen receptor (CAR)-T therapy designed to treat relapsed\/refractory systemic lupus erythematosus (SLE).","og_url":"https:\/\/flcube.com\/?p=67179","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-03T05:47:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67179#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67179"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus","datePublished":"2026-06-03T05:47:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67179"},"wordCount":494,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67179#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67179","url":"https:\/\/flcube.com\/?p=67179","name":"CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-03T05:47:53+00:00","description":"CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced it has received clinical trial approval from China's National Medical Products Administration (NMPA) for SYS 6063, an innovative mRNA-LNP-based dual-target chimeric antigen receptor (CAR)-T therapy designed to treat relapsed\/refractory systemic lupus erythematosus (SLE).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67179#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67179"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67179#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67179"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67179\/revisions"}],"predecessor-version":[{"id":67181,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67179\/revisions\/67181"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}